Citations

Clear

2358 citation(s) found for "Yu, Long".

Clinicopathologic Features and Long-Term Outcomes of Adult Hypopigmented Mycosis Fungoides
Park, Jong Bin, Liao, Viviane , Pürnak, Seda , Huen, Auris, Iyer, Swaminathan P., Pierog, Olivia , Leibovit‐Reiben, Zachary , Mangold, Aaron R., Scribner, Jane, Talluru, Sai , Stockard, A R, Vroman, Jenna , Weiner, Jeffrey, Allen, Pamela B., Rozati, Sima, Leibovit-Reiben, Zachary , Stockard, Alyssa L, Park, Jong Bin, Geller, Shamir , Huen, Auris , Mangold, Aaron R. , Rozati, Sima

Mayo Clinic

JAMA Dermatology | June 17, 2026 | Volume: 162 | Issue: 8 | Pages: 780

10.1001/jamadermatol.2026.1793 | PMID 42307910 Get It

Importance Hypopigmented mycosis fungoides (HMF) is uncommon in adults, and data on clinicopathologic features and long-term outcomes remain sparse. Objective To investigate the clinicopathologic features and outcomes of adults with HMF in a large multicenter cohort. Design, Setting, and Participants This retrospective multicenter cohort study conducted from January 2011 to October 2023 at 6 US tertiary referral centers and included adults (18 years or older at diagnosis) with biopsy-confirmed HMF and hypopigmentation documented at diagnosis, with a median (range) follow-up of 39 (1-347) months. Data were analyzed from February to December 2025. Exposures Clinical variant, immunophenotype predominance, and polymerase chain reaction–based T-cell receptor ( TCR ) gene rearrangement in peripheral blood and/or skin. Main Outcomes and Measures Best overall response, defined as complete response, partial response, stable disease, or progressive disease, and progression to a higher stage. Results The cohort included 224 adults with HMF (median [range] age, 44 [18-74] years), of whom 164 (73%) were women (60 men [27%]), 5 (2%) were Asian individuals, 1 (0.4%) was a Hispanic/Latino individual, 1 (0.4%) was a Middle Eastern individual, 19 (8%) were White individuals, and 186 (83%) were Black individuals; 219 (98%) presented with early-stage disease. Most had hypopigmented lesions only (159 [71%]), whereas 65 (29%) exhibited mixed-variant mycosis fungoides; outcomes were similar between groups. Among 141 patients with available immunophenotyping, 88 (63%) had CD8-positive predominance. Among 207 treated patients, most (179 [90%]) received skin-directed therapy alone. Among 198 evaluable patients, the best overall response was complete response for 52 (26%), partial response for 101 (51%), stable disease for 34 (17%), and progressive disease for 11 (6%). Over a median (range) follow-up of 39 (1-347) months, 14 of 224 patients (6%) experienced progression to a higher stage, including 5 of 219 patients (2%) with early-stage disease at baseline who experienced progression to advanced-stage disease. Peripheral blood TCR monoclonality was detected in 23 of 85 tested patients (27%) and was associated with poorer treatment response but not with disease progression. Conclusions and Relevance The finding of this cohort study suggest that adult HMF demonstrated a generally indolent course, with favorable response to skin-directed therapy, irrespective of immunophenotype or mixed-variant presentation. Peripheral blood TCR monoclonality was associated with lower treatment response but not disease progression.
Guillain-Barré syndrome following intracranial hemorrhage: a systematic review of case reports
Vallamchetla, Sai Krishna , Pasya, Sai Kumar Reddy , Gronseth, Gary, Davalos, Long, Gronseth, Gary

Mayo Clinic

Frontiers in Neurology | June 17, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fneur.2026.1789597 | PMID 42388706 Get It

Introduction Guillain-Barré syndrome (GBS) is an autoimmune polyradiculopathy linked to various triggers. Recently, several case reports described GBS development following intracranial hemorrhage (ICH), posing diagnostic and therapeutic challenges. Methods PubMed and EMBASE were searched from inception till February 2023 for case reports. Two reviewers independently screened the articles and extracted data using a standardized form. The extracted data were then analyzed narratively. Quality was assessed with the JBI Checklist for Case Reports. Results Twenty-three cases from 11 countries were identified (14 males, mean age of 60.1 years). Onset of GBS occurred after a median of 9 days (range 2–24) post-ICH, with intracerebral hemorrhage being the most common antecedent (39.1%), followed by subarachnoid (26.1%) and subdural hemorrhage (21.7%). Electrophysiology showed predominantly axonal variants, while CSF consistently demonstrated albuminocytologic dissociation with positive antiganglioside antibodies in five cases. The clinical course was severe, marked by rapid progression to nadir (median 2.5 days), profound functional impairment (average Hughes Functional Grading Scale: 4.57 ± 0.66), and a high rate of respiratory failure requiring mechanical ventilation (78.3%). Axonal variants were associated with higher rates of mechanical ventilation and poorer outcomes than demyelinating forms. Among the 21 patients who received immunomodulatory treatment, 3 (14.3%) showed complete recovery, 13 (61.9%) had partial recovery, 3 (14.3%) had a poor recovery, and 2(9.5%) died at last follow up. Conclusion GBS may complicate recovery after ICH and appears to present with an aggressive course, particularly in axonal variants. Clinicians should consider GBS when patients with ICH develop progressive, symmetrical weakness unexplained by the initial brain injury, as prompt initiation of immunotherapy may improve outcomes.
Long-term corticosteroid use elevates 90-day medical complications but not 5-year surgical complications after shoulder arthroplasty
Holmstrom, Joshua Aaron , Hiredesai, Annika N. , Holle, Alejandro M. , Braithwaite, Collin , Hassebrock, Jeffrey D. , Holmstrom, Joshua A , Braithwaite, Collin L , Hassebrock, Jeffrey D , Holle, Alejandro

Mayo Clinic

Shoulder & Elbow | June 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/17585732261460807 | PMID 42318159 Get It

Background Long-term corticosteroid (LTC) use is a known risk factor for adverse outcomes after various surgical procedures. However, the impact of LTC use on surgical complications after TSA remains underexplored. This study aims to assess the influence of LTC use on 90-day and 5-year complications following TSA. Methods A retrospective cohort study utilizing the PearlDiver database was conducted. Patients undergoing primary TSA with a minimum 5-year follow-up were included. LTC users were propensity-matched 1:10 with controls based on demographic variables and comorbidities. Postoperative complications within 90 days of surgery and long-term complications within 5 years were compared between groups. Multivariable logistic regressions were used to compare complications controlling for demographic variables and comorbidities. Results In a matched cohort of 556 LTC users to 4942 controls, corticosteroid users exhibited a 2.91-fold higher risk of pneumonia (95% CI: 1.69–4.80, p < 0.001) and a 2.19-fold higher risk of venous thromboembolism (VTE) (95% CI: 1.30–3.51, p = 0.001) within 90 days following TSA. No significant differences in 5-year surgical outcomes were observed. Discussion LTC users are at a heightened risk for 90-day medical complications, including pneumonia and VTE following TSA. However, their 5-year risk of surgical complications was comparable to patients without LTC use.
Delayed graft function and long-term outcomes after deceased donor kidney transplantation: insights from mate-kidney analysis
Valencia, Oscar A. Garcia, Alrifai, Ahmed, Mahgoub, Mohammed, Mour, Girish, Smith, Byron, Bentall, Andrew J., Issa, Naim , Riad, Samy, Garcia Valencia, Oscar A, Alrifai, Ahmed Zeen Alabedeen, Mahgoub, Mohammed Y, Issa, Naim S, Cortez, Alexander R. , Valencia, Oscar A. Garcia , Mour, Girish , Bentall, Andrew , Jadlowiec, Caroline C. , Amer, Hatem , Riad, Samy

Mayo Clinic

Transplant International | June 16, 2026 | Volume: 39 | Issue: No issue available | Pages: No page available

10.3389/ti.2026.16526 | PMID 42382229 Get It

Delayed graft function (DGF) is a frequent complication after deceased donor kidney transplantation, yet its long-term impact remains understudied. Heterogeneous populations, short follow-up, and inadequate control of donor-related factors have limited prior studies. Using the Scientific Registry of Transplant Recipients (2005–2024), we evaluated the association between DGF and long-term graft outcomes, including a mate-kidney (same donor, discordant DGF status) analysis to isolate its independent effect. We identified 103,678 dialysis-dependent deceased donor kidney recipients maintained on tacrolimus and mycophenolate. Mixed-effects Cox models, adjusted for donor, recipient, immunologic, and procurement factors. DGF occurred in 30.1% of recipients and was associated with increased death-censored graft failure (HR 1.40; 95% CI 1.33–1.47) and overall graft failure (HR 1.27; 95% CI 1.23–1.31). DGF recipients had higher rejection rates at 6 (6.0% vs. 4.7%) and 12 months (8.9% vs. 7.3%), longer hospital stay, and higher 1-year rehospitalization. In the mate-kidney analysis (6,818 donors), DGF remained strongly associated with death-censored graft failure (HR 1.58; 95% CI 1.39–1.80) and overall graft failure (HR 1.35; 95% CI 1.25–1.46), confirming the independent effect of DGF. DGF is a strong predictor of adverse long-term outcomes irrespective of rejection and warrants targeted prevention strategies and intensified follow-up.
Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies
Braun, David, Dana, Nicholas, Hernan, Hilary R., Scribano, Christina, Johnson, Christin , Vedder, Lindsey, Euw, Erika von , Zweng, Julie, Wargowski, Ellen, Sunil, Aishwarya , Sharma, D, Routh, Josh, Rexroad, Katherine, McDonnell, Payton , Jergens, Victor, Costa, Catarina, Zuniga, Richard, Patel, Paras M., Martin, Robert C.G., Majeed, Umair, Mukhopadhyay, Debabrata, Lou, Yanyan, Kokabi, Nima, Jakub, James W., Hays, David, Godwin, Andrew K., Giffi, Victoria, Gelbard, Alexander, Friedl, Andreas, Duimstra, Emma Kate, Dronca, Roxana S., Chen, Ruqin, Chalfin, Heather, Broome, Barbara , Babiker, Hani M., Chandra, Tarun, Caenepeel, Sean, Hrycyniak, Laura , Sood, Chetan , Ramos, Hilario, Patel, Premal , Advani, Pooja, Gierman, Hinco J., Taube, Janis, Braun, David , Sahni, Shalini, Scribano, Christina M. , Wargowski, Ellen , Zuniga, Richard, Toia, Giuseppe V. , Martin, Robert C.G. , Majeed, Umair , Mukhopadhyay, Debabrata , Lou, Yanyan , Kokabi, Nima , Jakub, James W. , Godwin, Andrew K. , Gelbard, Alexander , Friedl, Andreas , Dronca, Roxana , Chen, Ruqin, Chalfin, Heather J., Babiker, Hani M. , Caenepeel, Sean , Ramos, Hilario J. , Patel, Premal, Advani, Pooja , Gierman, Hinco J. , Taube, Janis M

Mayo Clinic

No container title available | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.05.26354635 Get It

Summary Functional ex vivo assays using live tumor tissues have demonstrated strong predictive accuracy for response to immune checkpoint inhibitors (ICIs) but are not scalable, requiring manual processing of large resections collected at academic centers. Here, an ex vivo live tumor fragment (LTF) platform was developed using standard-of-care biopsies from 228 patients with suspected malignancy collected across prospective, multicenter observational trials and biobanks. Hierarchical clustering of ICI-mediated changes in cytokine production identified two groups: responders and nonresponders. A binary classifier (elive index) using 8 cytokines achieved an AUC of 0.99 for cluster prediction. elive index correctly predicted clinical benefit in 93% (26/28) of patients ( P = 3.2x10 -5 ) and accurately identified 83% (10/12) of objective responders. Critically, elive responders were identified among biomarker-negative patients, highlighting the platform as a scalable approach that complements existing companion diagnostics and expands the population of patients identified to benefit from ICI therapy.
Guillain-Barré Syndrome Following Intracranial Hemorrhage: A Systematic Review of Case Reports (P1-9.009)
Pasya, Sai Kumar Reddy , Vallamchetla, Sai Krishna, Gronseth, Gary, Davalos, Long, Vallamchetla, Sai Krishna , Gronseth, Gary

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000213235 Get It

Impact of Disease-modifying Treatments on Long-term Changes in the Choroid Plexus in Subjects With Radiologically Isolated Syndrome (P4-19.008)
Stankoff, B, Ricigliano, Vito AG, Mondot, Lydiane, Cohen, Mikael, Panah, Arya Yazdan, Kantarci, O, Okuda, Darin, Frenay, Christine Lebrun, Landes-Château, Cassandre , Stankoff, Bruno , Ricigliano, Vito A. G. , Mondot, Lydiane , Cohen, Mikaël , Yazdan-Panah, Arya , Lebrun‐Frénay, Christine

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216101 Get It

Tumefactive Demyelination at Multiple Sclerosis Onset Associates With Less Severe Long-term Disability (P4-19.006)
Neyal, Nur , Atkinson, E. C., Tarlton, Caitlin, Schwarz, Christopher, Decker, Paul, Kosel, Matthew, Son, Jiye , Keegan, Mark , Kantarci, Kejal, Kantarci, Orhun, Tobin, W., Aboseif, Albert , Atkinson, Elizabeth, Jackson-Tarlton, Caitlin S. , Schwarz, Christopher, Kosel, Matthew , Kantarci, Kejal , Kantarci, O, Zeydan, Burcu

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217162 Get It

Too Long; Didn’t Read: How Epilepsy Patients Navigate Illness Through Reddit (P9-11.010)
Silla, Laura, Hoerth, Matthew, Noe, Katherine, Silla, Laura J., Hoerth, Matthew T., Noe, Katherine H.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215833 Get It